530 canadians with kidney disease share real-world drug results
NCT ID NCT02925221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 530 adults with autosomal dominant polycystic kidney disease (ADPKD) who were already taking the drug tolvaptan (JINARC™). Researchers wanted to see how the medication affected their quality of life, pain, and daily activities, as well as how long it took before they needed dialysis or a kidney transplant. The study did not test a new treatment—it simply observed real-world experiences to better understand the drug's impact.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Edmonton, Alberta, Canada
-
Study site
London, Ontario, Canada
-
Study site
Ottawa, Ontario, Canada
-
Study site
Toronto, Ontario, Canada
-
Study site
Montreal, Quebec, Canada
-
Study site
Québec, Quebec, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Carb diet calm kidney disease inflammation?
- Large study tracks kidney disease progression in thousands of patients
- New hope for dialysis patients: non-surgical kidney reduction could clear the way for transplant
- Could a drug for acromegaly protect kidneys in polycystic disease?
- Drug interaction study: VX-407 and oral contraceptives
- Could a keto diet help slow kidney disease? new study seeks answers